Last updated: September 5, 2026
Trimethoprim sulfate and polymyxin B sulfate ophthalmic solution is a mature, low-cost prescription antibiotic combination marketed primarily as Polytrim and generic equivalents. The product has limited patent protection, no meaningful new-drug exclusivity, and a fragmented generic supply base. Its financial trajectory is driven by prescription volume, payer reimbursement, pharmacy pricing, and manufacturing continuity rather than innovation or exclusivity.
Public companies generally do not report product-level revenue for this combination. The market therefore is best assessed through regulatory status, generic competition, pricing structure, prescription demand, and substitution by newer ophthalmic antibiotics.
What is trimethoprim sulfate and polymyxin B sulfate used for?
The product is an ophthalmic antibacterial solution used to treat bacterial infections of the external eye, including conjunctivitis and blepharitis. Each milliliter commonly contains 1 mg of trimethoprim, supplied as trimethoprim sulfate, and 10,000 units of polymyxin B sulfate.[1]
The combination provides activity against a range of gram-positive and gram-negative organisms. Trimethoprim inhibits bacterial folate metabolism, while polymyxin B disrupts bacterial cell membranes. The product is generally used for short treatment courses and is not a chronic therapy.
Core product characteristics
| Attribute |
Description |
| Active ingredients |
Trimethoprim sulfate and polymyxin B sulfate |
| Dosage form |
Sterile ophthalmic solution |
| Common brand |
Polytrim |
| Typical concentration |
Trimethoprim 1 mg/mL; polymyxin B 10,000 units/mL |
| FDA status |
Prescription drug |
| Main indications |
Bacterial conjunctivitis and related external ocular infections |
| Commercial category |
Mature branded-generic ophthalmic antibiotic |
| Primary route |
Topical ocular administration |
| Typical treatment duration |
Short course, generally about 7 to 10 days |
The product is not a biologic. Biosimilar regulation does not apply. Competitive risk comes from generic versions and therapeutic substitutes, not biosimilar entry.
What is the FDA regulatory status of Polytrim and generic equivalents?
Polytrim was approved decades ago, and the product has long operated in a mature prescription market. The original new-drug exclusivity period expired many years ago. Generic manufacturers can enter through abbreviated new drug applications, subject to FDA requirements for pharmaceutical equivalence, quality, sterility, stability, and bioequivalence or applicable in vitro standards.[2]
The commercial market includes branded Polytrim, authorized or private-label equivalents, and generic trimethoprim sulfate/polymyxin B sulfate ophthalmic solutions. The exact active manufacturer list can change because ophthalmic suppliers periodically enter, exit, transfer products, or experience manufacturing disruptions.
FDA regulatory considerations include:
- Sterility assurance for the ophthalmic product.
- Container-closure integrity.
- Preservative performance where applicable.
- Manufacturing controls for a low-volume sterile liquid.
- Labeling consistency with the reference product.
- Facility inspections and compliance history.
- Availability of the product in the FDA drug-supply chain.
The main regulatory risk is supply interruption rather than loss of exclusivity.
What patents protect trimethoprim sulfate and polymyxin B sulfate ophthalmic solution?
The active ingredients are old compounds with no commercially meaningful remaining composition-of-matter patent protection. The basic combination has been marketed for decades, making the original product estate highly mature.
Patent categories
| Patent category |
Current commercial relevance |
| Composition-of-matter patents |
Expired |
| Original combination patents |
Expired or no longer commercially material |
| Method-of-use patents |
No material exclusivity expected for ordinary bacterial eye infections |
| Formulation patents |
Limited relevance; possible supplier-specific claims may exist |
| Manufacturing patents |
Potentially relevant to individual producers but unlikely to block market entry broadly |
| Device or container patents |
Could apply to a particular package but would not protect the active ingredient market |
A current Orange Book review should be used for transaction or litigation diligence because listed patents and product records can change. Publicly available product information does not indicate a meaningful active Orange Book patent barrier that would delay ordinary generic entry.[3]
When does trimethoprim and polymyxin B lose exclusivity?
The product lost practical market exclusivity decades ago. No material future patent cliff is expected for the standard ophthalmic solution.
| Milestone |
Commercial effect |
| Original FDA approval |
Established the reference product |
| Expiration of original exclusivity |
Opened the market to generic competition |
| Generic ANDA approvals |
Created multi-source pricing |
| Current period |
Mature, low-margin branded-generic market |
| Future outlook |
Stable demand with periodic supplier and pricing changes |
Because the market is already genericized, future financial changes will not resemble the revenue erosion that follows a modern small-molecule patent expiration. Most price compression has already occurred.
How many patents cover the product?
No single patent family appears to provide broad, commercially significant protection for the active combination today. Any surviving claims would more likely concern a specific formulation, packaging configuration, manufacturing process, or delivery technology.
This distinction matters. A process patent owned by one manufacturer may affect that manufacturer’s production economics but generally does not prevent another company from making the same ophthalmic combination through a different process. Similarly, a package patent would not normally protect the underlying drug market.
What formulations are protected?
The conventional product is a sterile aqueous ophthalmic solution. Its commercial value comes from the combination of established active ingredients rather than a differentiated delivery system.
Potentially protectable technical areas include:
- Preservative systems.
- Buffering and pH control.
- Improved chemical stability.
- Low-sorption containers.
- Dropper delivery systems.
- Unit-dose packaging.
- Preservative-free formulations.
- Extended shelf-life manufacturing processes.
These areas can support product differentiation, but they do not appear to have created a dominant, publicly visible patent moat around the standard Polytrim formulation.
Which companies compete in the trimethoprim-polymyxin B market?
Competition comes from both suppliers of the same combination and manufacturers of alternative ophthalmic antibiotics.
Direct competitors
The direct competitive set includes:
- The Polytrim brand.
- Generic trimethoprim sulfate and polymyxin B sulfate ophthalmic solutions.
- Pharmacy and wholesaler private-label products.
- Contract-manufactured ophthalmic antibiotic products.
Brand ownership and distribution arrangements may differ by market and over time. Product-level revenue and market-share figures are generally not disclosed by manufacturers because the products are low-revenue components of broader ophthalmology portfolios.
Therapeutic substitutes
| Alternative |
Competitive position |
| Tobramycin ophthalmic |
Common low-cost alternative for bacterial eye infections |
| Erythromycin ophthalmic ointment |
Used where ointment delivery is preferred |
| Moxifloxacin ophthalmic |
Broad-spectrum fluoroquinolone with stronger pricing in some settings |
| Ofloxacin ophthalmic |
Generic fluoroquinolone substitute |
| Besifloxacin ophthalmic |
Branded fluoroquinolone with differentiated commercial positioning |
| Azithromycin ophthalmic |
Used in selected ocular surface indications |
Clinical selection depends on suspected organism, local resistance patterns, patient age, formulation preference, allergy history, and prescriber habits. In routine uncomplicated conjunctivitis, low-cost generic products face substantial substitution pressure.
What is the market size and financial trajectory?
A precise global or U.S. revenue figure cannot be derived from public manufacturer disclosures. The product is sold by multiple suppliers, and companies generally report ophthalmology or pharmaceuticals revenue at a level too broad to isolate this combination.
The financial profile is nevertheless clear:
- Revenue is mature rather than growth-oriented.
- Unit volume is relatively stable and linked to bacterial eye-infection diagnosis.
- Average selling price is constrained by generic competition.
- Brand revenue is exposed to formulary substitution.
- Manufacturer profitability depends on production efficiency and supply reliability.
- Shortages can temporarily increase pricing or volume for remaining suppliers.
Revenue drivers
| Driver |
Expected effect |
| Generic entry |
Reduces price and branded share |
| Prescription volume |
Supports stable unit demand |
| Retail reimbursement |
Determines pharmacy economics |
| Medicaid and managed-care substitution |
Favors low-cost generics |
| Manufacturing interruptions |
Can shift volume to available suppliers |
| Ophthalmology prescribing trends |
Affects category demand |
| Antibiotic stewardship |
May limit inappropriate use |
| Supplier consolidation |
Can improve pricing temporarily but increases shortage risk |
The product’s financial trajectory is best characterized as stable-to-declining nominal revenue per supplier, offset by recurring demand and occasional supply-driven price increases. It is unlikely to generate material organic growth without a new formulation, a proprietary delivery device, a preservative-free version, or a broader clinical indication.
What generic entry risks exist?
Generic entry risk is already realized. The relevant commercial question is not whether generics can enter, but how many active suppliers remain in the market at any given time.
Generic competition creates four principal risks:
- Price erosion as pharmacies substitute among equivalent products.
- Loss of branded prescriptions through formulary controls.
- Contract losses to wholesalers and group purchasing organizations.
- Margin compression when raw-material, packaging, or sterility costs rise.
The market can still experience temporary price increases when one or more sterile ophthalmic manufacturers encounter a shortage, plant issue, recall, or discontinuation. Such increases are usually unstable because other suppliers can capture demand once capacity returns.
Are there Paragraph IV challenges or patent litigation?
Paragraph IV litigation is unlikely to be a material current issue for the standard product. A Paragraph IV filing challenges a listed patent as invalid, unenforceable, or not infringed. With no apparent commercially significant active patent barrier around the conventional combination, there is limited incentive for a high-value Paragraph IV dispute.
Potential disputes could still arise over:
- A newly listed formulation patent.
- A preservative-free product.
- A delivery device.
- An abbreviated application alleging patent invalidity.
- Manufacturing or trade-secret claims between suppliers.
- Product-quality, labeling, or facility-compliance issues.
No major, current patent litigation is publicly associated with the ordinary trimethoprim sulfate and polymyxin B sulfate ophthalmic solution market in the available public record. Litigation exposure is therefore lower than for protected branded ophthalmic products.
What licensing deals affect the product?
The standard combination has limited licensing value because the active ingredients are old and generic. Commercial arrangements are more likely to involve:
- Contract manufacturing.
- Private-label distribution.
- Product rights transfers.
- Wholesale supply agreements.
- Regional commercialization rights.
- Packaging or delivery technology.
Large upfront licensing payments are unlikely for the conventional product. A licensing opportunity would have greater value if tied to a differentiated formulation, preservative-free delivery, pediatric packaging, or a broader ophthalmic platform.
How strong is the patent estate?
The patent estate is weak for the standard product and potentially stronger only for a differentiated formulation or delivery system.
| Criterion |
Assessment |
| Active-ingredient protection |
Very weak |
| Remaining exclusivity |
None expected for the standard product |
| Formulation differentiation |
Limited |
| Manufacturing barriers |
Moderate for sterile production |
| Regulatory barrier |
Moderate because ophthalmic products require sterility controls |
| Generic substitution risk |
High |
| Litigation risk |
Low for the conventional product |
| Revenue durability |
Dependent on volume and supply continuity |
The most important barrier is operational, not intellectual property-based. Sterile ophthalmic manufacturing requires validated facilities, quality systems, specialized filling equipment, and reliable component supply. These requirements can limit the number of dependable suppliers even when legal entry is open.
What generic launch scenarios are most likely?
Base case
Multiple generic suppliers remain active. Prices stay low, demand remains relatively stable, and the brand retains limited share through physician familiarity, formulary placement, or patient preference.
Upside scenario
A shortage at a competing manufacturer shifts volume to available suppliers. Revenue and gross margin increase temporarily, but the effect fades as supply normalizes.
Downside scenario
A supplier exits, reimbursement declines, or a competing low-cost antibiotic captures prescriptions. Unit economics weaken, and manufacturers reduce production or discontinue the product.
Differentiated-product scenario
A supplier introduces a preservative-free or improved-delivery formulation. The product may obtain better pricing, but commercial success would depend on clinical adoption, reimbursement, and any resulting regulatory or patent protection.
What is the geographic coverage?
The combination has broad international relevance because trimethoprim and polymyxin B are established antibacterial agents. Commercial availability varies by country, regulatory classification, brand ownership, and local generic manufacturing.
The United States is primarily a multi-source prescription market. In other jurisdictions, the product may be sold under different brand names, as a generic ophthalmic solution, or under national antibiotic-prescribing restrictions. Geographic revenue is likely concentrated in markets with established ophthalmic prescription channels and reimbursement systems.
International growth is constrained by:
- Local registration requirements.
- Sterile manufacturing capacity.
- Import controls.
- Country-specific antibiotic rules.
- Local pricing and reimbursement.
- Different standards for preservatives and packaging.
Key Takeaways
- Trimethoprim sulfate and polymyxin B sulfate ophthalmic solution is a mature generic antibiotic combination.
- Polytrim is the principal historical brand, but generic competition is the dominant commercial force.
- The original active-ingredient and combination protections are no longer meaningful market barriers.
- No material future patent cliff is expected because exclusivity has already expired.
- Paragraph IV litigation and major patent disputes are unlikely for the standard formulation.
- Product-level revenue is not publicly reported with sufficient granularity for a reliable standalone forecast.
- Financial performance depends on prescription volume, reimbursement, production cost, and supply continuity.
- Sterile ophthalmic manufacturing is a more important barrier than patent ownership.
- Temporary revenue upside can arise from competitor shortages, but long-term growth prospects are limited.
- A preservative-free formulation, delivery innovation, or proprietary packaging system would be required to create meaningful differentiation.
FAQs About Trimethoprim Sulfate and Polymyxin B Sulfate
Is trimethoprim-polymyxin B still a profitable drug?
It can remain profitable for efficient manufacturers with reliable sterile production, but it is unlikely to produce high margins because several generic suppliers and therapeutic alternatives constrain pricing.
Is Polytrim a generic antibiotic?
Polytrim is the historical branded product. Trimethoprim sulfate and polymyxin B sulfate ophthalmic solution is also available from generic manufacturers.
Can a new company launch a generic version?
A company can pursue an FDA abbreviated application if it meets applicable requirements for pharmaceutical equivalence, product quality, sterility, manufacturing controls, and labeling.
Does the product have biosimilar competition?
No. Biosimilar regulation applies to biological products. This product is a conventional small-molecule ophthalmic drug and faces generic competition instead.
Could a preservative-free version command a premium?
Potentially. A preservative-free formulation could appeal to patients with ocular-surface sensitivity or repeated-use needs, but pricing power would depend on clinical differentiation, reimbursement, manufacturing cost, and regulatory protection.
References
- U.S. Food and Drug Administration. (n.d.). Polytrim: Trimethoprim sulfate and polymyxin B sulfate ophthalmic solution prescribing information. DailyMed.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process. FDA.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.
- U.S. Food and Drug Administration. (n.d.). FDA Orange Book patent and exclusivity information. FDA.
